A large majority of older Americans feel that health insurance—including Medicare—should cover anti-obesity medications, ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The move gives Rhythm full global control of the drug, which is approved in the USA and Europe to treat certain rare genetic forms of obesity. Rhythm agreed to pay RareStone $6.3 million and return ...

Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin ...

Due to obesity, certain health issues can occur both mentally and physically. These individuals may have higher chances of experiencing a chronic disease in this case. People who suffer from the ...

The scientists followed up on these results with human genetic data, including large cohorts that contained sequencing data from individuals with early onset, severe obesity. Variants in DENND1B also ...

Though frustrating and difficult, hip pain is often preventable—and even when it isn't, it's nearly always treatable.

Learn about the 4 essential types of diabetes, their unique characteristics, risk factors, and management strategies to ...

CRANBURY, NJ, USA I March 31, 2025 I Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The University of Texas at Austin and Tec de Monterrey have launched a research center with the goal of improving the health ...

Policymakers should focus on both obesity prevention and better access to treatment for those already living with obesity.